BioAdvance Capital Fuels Life Sciences Innovation with Nine New Investments Expands Portfolio with Cutting-Edge Innovations in Gene Therapy, AI-Driven Drug Discovery, and Precision Medicine and Reaffirms Investments in Existing Portfolio Philadelphia, PA – February 25, 2025 – In 2024, BioAdvance Capital continued its mission to foster early-stage healthcare innovation in…
Read More
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes See more here
Read More
Science: There Will Be Blood Is mimicking the cells that carry hemoglobin the key to a blood substitute? See more here
Read More
The UM BioPark is a beacon for early-stage technology ventures The research park’s perfectly matched location and array of startup-supporting resources makes it an invaluable pillar for a growing number of life science startups — and the entire Maryland ecosystem. See more here
Read More
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - $125 million private placement investment completed with leading institutional investors will support cash runway…
Read More
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies See more here
Read More
SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting See more here
Read More
Venatorx Pharmaceuticals to Present at IDWeek 2023 - New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam - MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer See more here
Read More
Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze Strados Labs’ RESP™ Biosensor is currently being used in a clinical trial at Lurie Children’s to determine if the technology can accurately detect wheezing and other symptoms of asthma exacerbation in children. See more…
Read More
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment Long-term dosing with REL-1017 was well-tolerated, with…
Read More